Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome

    Research output: Contribution to journalLetterResearchpeer-review

  4. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Response to Aviv et al

    Research output: Contribution to journalLetterResearchpeer-review

  2. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival

    Research output: Contribution to journalLetterResearchpeer-review

  • Lydia Scarfò
  • Thomas Chatzikonstantinou
  • Gian Matteo Rigolin
  • Giulia Quaresmini
  • Marina Motta
  • Candida Vitale
  • Jose Antonio Garcia-Marco
  • José Ángel Hernández-Rivas
  • Fatima Mirás
  • Mónica Baile
  • Juan Marquet
  • Carsten U Niemann
  • Gianluigi Reda
  • Talha Munir
  • Eva Gimeno
  • Monia Marchetti
  • Francesca Maria Quaglia
  • Marzia Varettoni
  • Julio Delgado
  • Sunil Iyengar
  • Ann Janssens
  • Roberto Marasca
  • Angela Ferrari
  • Carolina Cuéllar-García
  • Gilad Itchaki
  • Martin Špaček
  • Lorenzo De Paoli
  • Luca Laurenti
  • Mark-David Levin
  • Enrico Lista
  • Francesca R Mauro
  • Martin Šimkovič
  • Ellen Van Der Spek
  • Elisabeth Vandenberghe
  • Livio Trentin
  • Ewa Wasik-Szczepanek
  • Rosa Ruchlemer
  • Dominique Bron
  • Maria Rosaria De Paolis
  • Giovanni Del Poeta
  • Lucia Farina
  • Myriam Foglietta
  • Massimo Gentile
  • Yair Herishanu
  • Tobias Herold
  • Ozren Jaksic
  • Arnon P Kater
  • Sabina Kersting
  • Lara Malerba
  • Lorella Orsucci
  • Viola Maria Popov
  • Paolo Sportoletti
  • Mohamed Yassin
  • Barbara Pocali
  • Gabor Barna
  • Annalisa Chiarenza
  • Gimena Dos Santos
  • Eugene Nikitin
  • Martin Andres
  • Maria Dimou
  • Michael Doubek
  • Alicia Enrico
  • Yervand Hakobyan
  • Olga Kalashnikova
  • Macarena Ortiz Pareja
  • Maria Papaioannou
  • Davide Rossi
  • Nimish Shah
  • Amit Shrestha
  • Oana Stanca
  • Niki Stavroyianni
  • Vladimir Strugov
  • Constantine Tam
  • Mihnea Zdrenghea
  • Marta Coscia
  • Kostas Stamatopoulos
  • Giuseppe Rossi
  • Alessandro Rambaldi
  • Emili' Montserrat
  • Robin Foà
  • Antonio Cuneo
  • Paolo Ghia
View graph of relations

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

Original languageEnglish
JournalLeukemia
Volume34
Issue number9
Pages (from-to)2354-2363
Number of pages10
ISSN0887-6924
DOIs
Publication statusPublished - Sep 2020

    Research areas

  • Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents/pharmacology, Betacoronavirus, COVID-19, Comorbidity, Coronavirus Infections/diagnosis, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell/complications, Male, Middle Aged, Pandemics, Pneumonia, Viral/diagnosis, Prognosis, Protein Kinase Inhibitors/pharmacology, Pyrazoles/pharmacology, Pyrimidines/pharmacology, Retrospective Studies, SARS-CoV-2, Severity of Illness Index, Surveys and Questionnaires

ID: 62329186